fbpx
Sunday, October 24, 2021 | 08:17 pm
blank
Tags Synthetic Biology

Tag: Synthetic Biology

Zymergen Plunges 68% After Saying Product Revenue Will Be ‘Immaterial’ in 2022, Removing CEO

Zymergen went public at $31 a share in April and traded as high as $48.50, valuing the company at $4.8 billion.

Stay Connected

73,275FansLike
443FollowersFollow
5,792FollowersFollow